Product Images Alendronate Sodium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Alendronate Sodium NDC 71205-048 by Proficient Rx Lp, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
The text describes a chart or graph that shows the cumulative incidence of hip fractures over a three-year study. The study includes patients who had radiographic vertebral fracture at the beginning of the study. The data compares a placebo group to a group taking alendronate sodium. The x-axis shows time in months and the y-axis shows the percentage of cumulative incidence.*
This is a prescription medication labeled as Alendronate Sodium 70mg in white to off-white, oval shaped, biconvex, uncoated tablets. It is a once-weekly dosage containing 4 tablets. Each tablet contains 91.363 mg of alendronate in sodium USP equivalent to 70 mg alendronic acid. The manufacturer is Aurobindo Pharma Limited Hyderabad-500 038, India. Lot number is 400000 SNEMASTER and it should be stored at 20° to 25°C (68° to 77°F). A medication guide must be dispensed to each patient. No non-English characters were recognized.*
This appears to be a table of data related to the increase in bone mineral density in postmenopausal women with osteoporosis who were treated with alendronate at a dosage of 10mg/day for three years. The data shows a mean percentage increase in BMD for the lumbar spine, femoral neck, and trochanter compared to a placebo. The exact numbers are not easily discernible from the provided text.*
This is a table displaying the mean percent change from baseline in Bone Mineral Density (BMD) in postmenopausal women with osteoporosis who were treated with Alendronate 10 mg/day compared to placebo. The data shows the time course of the effect of the treatment on the BMD percent change from the baseline, measured at the lumbar spine. The study was a multinational trial and the data was recorded over the course of 36 months.*
The given text seems to be a report on the effect of Alendronate on Serum Alkaline Phosphatase in Paget's Disease of Bone. The text includes a table with mean % change from baseline for Alendronate, Placebo, and Etidronate. The study was conducted on two groups - a multinational group and a US group, with 27 and 41 participants, respectively, over a period of 6 months.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.